Review





Similar Products

vx765  (InvivoGen)
96
InvivoGen vx765
Vx765, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vx-765/VX-765/pm42174265-415-1-28
Average 96 stars, based on 1 article reviews
vx765 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
vx 765  (MedChemExpress)
97
MedChemExpress vx 765
Vx 765, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vx-765/Belnacasan/pmc13286026-57-4-18
Average 97 stars, based on 1 article reviews
vx 765 - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
caspase 1 inhibitor vx 765  (MedChemExpress)
97
MedChemExpress caspase 1 inhibitor vx 765
Caspase 1 Inhibitor Vx 765, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vx-765/Belnacasan/pm42302943-118-13-20
Average 97 stars, based on 1 article reviews
caspase 1 inhibitor vx 765 - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
belnacasan vx 765  (MedChemExpress)
97
MedChemExpress belnacasan vx 765
In vivo anti-tumor efficacy and immune evaluation (A) Schematic illustration of the in vivo treatment procedure. (B) Average tumor growth curves of each group. (C) H&E and Ki-67 staining of tumor sections (scale bar: H&E, 200 μm; Ki-67, 100 μm). (D) Immunofluorescence staining of NLRP3, C-Cas-1, and GSDMD-N in tumor sections (scale bar: 100 μm). (E) Schematic illustration of the immune evaluation procedure. (F–M) Flow cytometry analysis of CD80 + CD86 + DCs in CD11c + cells (F), CD8 + CD3 + T cells in CD45 + cells (G), CD4 + CD3 + T cells in CD45 + cells (H), IFN-γ + CD8 + T cells in CD3 + CD45 + cells (I), CD49b + NK cells in CD3 − CD45 + cells (J), the ratio of M1 to M2 macrophages (K), Foxp3 + CD4 + Tregs in CD3 + CD45 + cells (L), and Gr-1 + CD11b + MDSCs in CD45 + cells (M). (N) ELISA assay for the detection of the cytokines TNF-α, IL-1β, IFN-γ, and IL-12p70 within the tumor. (O) Schematic illustration of the treatment and evaluation procedure in combination with <t>VX-765.</t> (P) Average tumor growth curves of each group. (Q–V) Flow cytometry analysis of DCs (Q), CD8 + T cells (R), CD4 + T cells (S), NK cells (T), MDSCs (U), and Arg-1 + MDSCs (V). (W) Schematic illustration of the treatment procedure in combination with αLy6G/Ly6C (Gr-1). (X) Average tumor growth curves of each group. (Y) Immunofluorescence staining of CD8 and CD4 in tumor sections (scale bar: 100 μm). The data were presented as mean ± SD from n = 5. Statistical significance was calculated by two-way ANOVA comparison test in (B) by day 10 and in (P) and (X), one-way ANOVA with Dunnett’s comparison test in (F)–(M), and with Tukey’s comparison test in (Q)–(V).
Belnacasan Vx 765, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vx-765/Belnacasan/pmc13293998-108-0-3
Average 97 stars, based on 1 article reviews
belnacasan vx 765 - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
hy 100579 belnacasan vx 765 mce  (MedChemExpress)
99
MedChemExpress hy 100579 belnacasan vx 765 mce
In vivo anti-tumor efficacy and immune evaluation (A) Schematic illustration of the in vivo treatment procedure. (B) Average tumor growth curves of each group. (C) H&E and Ki-67 staining of tumor sections (scale bar: H&E, 200 μm; Ki-67, 100 μm). (D) Immunofluorescence staining of NLRP3, C-Cas-1, and GSDMD-N in tumor sections (scale bar: 100 μm). (E) Schematic illustration of the immune evaluation procedure. (F–M) Flow cytometry analysis of CD80 + CD86 + DCs in CD11c + cells (F), CD8 + CD3 + T cells in CD45 + cells (G), CD4 + CD3 + T cells in CD45 + cells (H), IFN-γ + CD8 + T cells in CD3 + CD45 + cells (I), CD49b + NK cells in CD3 − CD45 + cells (J), the ratio of M1 to M2 macrophages (K), Foxp3 + CD4 + Tregs in CD3 + CD45 + cells (L), and Gr-1 + CD11b + MDSCs in CD45 + cells (M). (N) ELISA assay for the detection of the cytokines TNF-α, IL-1β, IFN-γ, and IL-12p70 within the tumor. (O) Schematic illustration of the treatment and evaluation procedure in combination with <t>VX-765.</t> (P) Average tumor growth curves of each group. (Q–V) Flow cytometry analysis of DCs (Q), CD8 + T cells (R), CD4 + T cells (S), NK cells (T), MDSCs (U), and Arg-1 + MDSCs (V). (W) Schematic illustration of the treatment procedure in combination with αLy6G/Ly6C (Gr-1). (X) Average tumor growth curves of each group. (Y) Immunofluorescence staining of CD8 and CD4 in tumor sections (scale bar: 100 μm). The data were presented as mean ± SD from n = 5. Statistical significance was calculated by two-way ANOVA comparison test in (B) by day 10 and in (P) and (X), one-way ANOVA with Dunnett’s comparison test in (F)–(M), and with Tukey’s comparison test in (Q)–(V).
Hy 100579 Belnacasan Vx 765 Mce, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vx-765/Ferrostatin-1/pm42242229-645-90-93
Average 99 stars, based on 1 article reviews
hy 100579 belnacasan vx 765 mce - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
vx 765  (InvivoGen)
96
InvivoGen vx 765
In vivo anti-tumor efficacy and immune evaluation (A) Schematic illustration of the in vivo treatment procedure. (B) Average tumor growth curves of each group. (C) H&E and Ki-67 staining of tumor sections (scale bar: H&E, 200 μm; Ki-67, 100 μm). (D) Immunofluorescence staining of NLRP3, C-Cas-1, and GSDMD-N in tumor sections (scale bar: 100 μm). (E) Schematic illustration of the immune evaluation procedure. (F–M) Flow cytometry analysis of CD80 + CD86 + DCs in CD11c + cells (F), CD8 + CD3 + T cells in CD45 + cells (G), CD4 + CD3 + T cells in CD45 + cells (H), IFN-γ + CD8 + T cells in CD3 + CD45 + cells (I), CD49b + NK cells in CD3 − CD45 + cells (J), the ratio of M1 to M2 macrophages (K), Foxp3 + CD4 + Tregs in CD3 + CD45 + cells (L), and Gr-1 + CD11b + MDSCs in CD45 + cells (M). (N) ELISA assay for the detection of the cytokines TNF-α, IL-1β, IFN-γ, and IL-12p70 within the tumor. (O) Schematic illustration of the treatment and evaluation procedure in combination with <t>VX-765.</t> (P) Average tumor growth curves of each group. (Q–V) Flow cytometry analysis of DCs (Q), CD8 + T cells (R), CD4 + T cells (S), NK cells (T), MDSCs (U), and Arg-1 + MDSCs (V). (W) Schematic illustration of the treatment procedure in combination with αLy6G/Ly6C (Gr-1). (X) Average tumor growth curves of each group. (Y) Immunofluorescence staining of CD8 and CD4 in tumor sections (scale bar: 100 μm). The data were presented as mean ± SD from n = 5. Statistical significance was calculated by two-way ANOVA comparison test in (B) by day 10 and in (P) and (X), one-way ANOVA with Dunnett’s comparison test in (F)–(M), and with Tukey’s comparison test in (Q)–(V).
Vx 765, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vx-765/VX-765/pm42162237-201-5-9
Average 96 stars, based on 1 article reviews
vx 765 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
vx  (MedChemExpress)
97
MedChemExpress vx
In vivo anti-tumor efficacy and immune evaluation (A) Schematic illustration of the in vivo treatment procedure. (B) Average tumor growth curves of each group. (C) H&E and Ki-67 staining of tumor sections (scale bar: H&E, 200 μm; Ki-67, 100 μm). (D) Immunofluorescence staining of NLRP3, C-Cas-1, and GSDMD-N in tumor sections (scale bar: 100 μm). (E) Schematic illustration of the immune evaluation procedure. (F–M) Flow cytometry analysis of CD80 + CD86 + DCs in CD11c + cells (F), CD8 + CD3 + T cells in CD45 + cells (G), CD4 + CD3 + T cells in CD45 + cells (H), IFN-γ + CD8 + T cells in CD3 + CD45 + cells (I), CD49b + NK cells in CD3 − CD45 + cells (J), the ratio of M1 to M2 macrophages (K), Foxp3 + CD4 + Tregs in CD3 + CD45 + cells (L), and Gr-1 + CD11b + MDSCs in CD45 + cells (M). (N) ELISA assay for the detection of the cytokines TNF-α, IL-1β, IFN-γ, and IL-12p70 within the tumor. (O) Schematic illustration of the treatment and evaluation procedure in combination with <t>VX-765.</t> (P) Average tumor growth curves of each group. (Q–V) Flow cytometry analysis of DCs (Q), CD8 + T cells (R), CD4 + T cells (S), NK cells (T), MDSCs (U), and Arg-1 + MDSCs (V). (W) Schematic illustration of the treatment procedure in combination with αLy6G/Ly6C (Gr-1). (X) Average tumor growth curves of each group. (Y) Immunofluorescence staining of CD8 and CD4 in tumor sections (scale bar: 100 μm). The data were presented as mean ± SD from n = 5. Statistical significance was calculated by two-way ANOVA comparison test in (B) by day 10 and in (P) and (X), one-way ANOVA with Dunnett’s comparison test in (F)–(M), and with Tukey’s comparison test in (Q)–(V).
Vx, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vx-765/Belnacasan/pmc13171487-42-0-4
Average 97 stars, based on 1 article reviews
vx - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier

Image Search Results


In vivo anti-tumor efficacy and immune evaluation (A) Schematic illustration of the in vivo treatment procedure. (B) Average tumor growth curves of each group. (C) H&E and Ki-67 staining of tumor sections (scale bar: H&E, 200 μm; Ki-67, 100 μm). (D) Immunofluorescence staining of NLRP3, C-Cas-1, and GSDMD-N in tumor sections (scale bar: 100 μm). (E) Schematic illustration of the immune evaluation procedure. (F–M) Flow cytometry analysis of CD80 + CD86 + DCs in CD11c + cells (F), CD8 + CD3 + T cells in CD45 + cells (G), CD4 + CD3 + T cells in CD45 + cells (H), IFN-γ + CD8 + T cells in CD3 + CD45 + cells (I), CD49b + NK cells in CD3 − CD45 + cells (J), the ratio of M1 to M2 macrophages (K), Foxp3 + CD4 + Tregs in CD3 + CD45 + cells (L), and Gr-1 + CD11b + MDSCs in CD45 + cells (M). (N) ELISA assay for the detection of the cytokines TNF-α, IL-1β, IFN-γ, and IL-12p70 within the tumor. (O) Schematic illustration of the treatment and evaluation procedure in combination with VX-765. (P) Average tumor growth curves of each group. (Q–V) Flow cytometry analysis of DCs (Q), CD8 + T cells (R), CD4 + T cells (S), NK cells (T), MDSCs (U), and Arg-1 + MDSCs (V). (W) Schematic illustration of the treatment procedure in combination with αLy6G/Ly6C (Gr-1). (X) Average tumor growth curves of each group. (Y) Immunofluorescence staining of CD8 and CD4 in tumor sections (scale bar: 100 μm). The data were presented as mean ± SD from n = 5. Statistical significance was calculated by two-way ANOVA comparison test in (B) by day 10 and in (P) and (X), one-way ANOVA with Dunnett’s comparison test in (F)–(M), and with Tukey’s comparison test in (Q)–(V).

Journal: Cell Reports Medicine

Article Title: STAT3 interference-driven nanomodulators reverse lipid metabolism-associated chemoresistance and potentiate metalloimmunotherapy in breast cancer

doi: 10.1016/j.xcrm.2026.102844

Figure Lengend Snippet: In vivo anti-tumor efficacy and immune evaluation (A) Schematic illustration of the in vivo treatment procedure. (B) Average tumor growth curves of each group. (C) H&E and Ki-67 staining of tumor sections (scale bar: H&E, 200 μm; Ki-67, 100 μm). (D) Immunofluorescence staining of NLRP3, C-Cas-1, and GSDMD-N in tumor sections (scale bar: 100 μm). (E) Schematic illustration of the immune evaluation procedure. (F–M) Flow cytometry analysis of CD80 + CD86 + DCs in CD11c + cells (F), CD8 + CD3 + T cells in CD45 + cells (G), CD4 + CD3 + T cells in CD45 + cells (H), IFN-γ + CD8 + T cells in CD3 + CD45 + cells (I), CD49b + NK cells in CD3 − CD45 + cells (J), the ratio of M1 to M2 macrophages (K), Foxp3 + CD4 + Tregs in CD3 + CD45 + cells (L), and Gr-1 + CD11b + MDSCs in CD45 + cells (M). (N) ELISA assay for the detection of the cytokines TNF-α, IL-1β, IFN-γ, and IL-12p70 within the tumor. (O) Schematic illustration of the treatment and evaluation procedure in combination with VX-765. (P) Average tumor growth curves of each group. (Q–V) Flow cytometry analysis of DCs (Q), CD8 + T cells (R), CD4 + T cells (S), NK cells (T), MDSCs (U), and Arg-1 + MDSCs (V). (W) Schematic illustration of the treatment procedure in combination with αLy6G/Ly6C (Gr-1). (X) Average tumor growth curves of each group. (Y) Immunofluorescence staining of CD8 and CD4 in tumor sections (scale bar: 100 μm). The data were presented as mean ± SD from n = 5. Statistical significance was calculated by two-way ANOVA comparison test in (B) by day 10 and in (P) and (X), one-way ANOVA with Dunnett’s comparison test in (F)–(M), and with Tukey’s comparison test in (Q)–(V).

Article Snippet: Belnacasan (VX-765) , MCE , Cat# HY-13205.

Techniques: In Vivo, Staining, Immunofluorescence, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Comparison